News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
577,015 Results
Type
Article (41305)
Company Profile (208)
Press Release (535502)
Section
Business (163826)
Career Advice (2059)
Deals (29878)
Drug Delivery (109)
Drug Development (76537)
Employer Resources (152)
FDA (14791)
Job Trends (12919)
News (291015)
Policy (28531)
Tag
Academia (2287)
Alliances (42608)
Alzheimer's disease (1177)
Approvals (14752)
Artificial intelligence (200)
Bankruptcy (274)
Best Places to Work (10071)
Biotechnology (112)
Breast cancer (203)
Cancer (1587)
Cardiovascular disease (129)
Career advice (1711)
Cell therapy (300)
Clinical research (62177)
Collaboration (591)
Compensation (213)
COVID-19 (2419)
C-suite (135)
Data (1449)
Diabetes (189)
Diagnostics (5261)
Earnings (61875)
Employer resources (138)
Events (83138)
Executive appointments (476)
FDA (15579)
Funding (523)
Gene therapy (231)
GLP-1 (672)
Government (4061)
Healthcare (15774)
Infectious disease (2523)
Inflammatory bowel disease (116)
Interviews (344)
IPO (13484)
Job creations (3258)
Job search strategy (1477)
Layoffs (397)
Legal (6145)
Lung cancer (249)
Manufacturing (225)
Medical device (10184)
Medtech (10189)
Mergers & acquisitions (16672)
Metabolic disorders (543)
Neuroscience (1574)
NextGen: Class of 2025 (5686)
Non-profit (3790)
Northern California (1614)
Obesity (319)
Opinion (238)
Parkinson's disease (113)
Patents (130)
People (47858)
Phase I (18842)
Phase II (27408)
Phase III (20961)
Pipeline (629)
Postmarket research (2344)
Preclinical (7499)
Radiopharmaceuticals (262)
Rare diseases (321)
Real estate (5006)
Regulatory (19922)
Research institute (2142)
Resumes & cover letters (319)
Southern California (1442)
Startups (3520)
United States (14827)
Vaccines (587)
Weight loss (241)
Date
Today (126)
Last 7 days (550)
Last 30 days (2469)
Last 365 days (30656)
2025 (2809)
2024 (31124)
2023 (34891)
2022 (45028)
2021 (48519)
2020 (46970)
2019 (40123)
2018 (30670)
2017 (29284)
2016 (28240)
2015 (32618)
2014 (25253)
2013 (20952)
2012 (22320)
2011 (23048)
2010 (20822)
Location
Africa (754)
Arizona (114)
Asia (37342)
Australia (5909)
California (3738)
Canada (1434)
China (355)
Colorado (176)
Connecticut (195)
Europe (81154)
Florida (617)
Georgia (112)
Illinois (398)
Indiana (202)
Japan (113)
Maryland (623)
Massachusetts (2959)
Michigan (143)
Minnesota (226)
New Jersey (1164)
New York (1119)
North Carolina (728)
Northern California (1614)
Ohio (149)
Pennsylvania (844)
South America (1039)
Southern California (1442)
Texas (515)
Washington State (353)
577,015 Results for "ra pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Celon Pharma Announces Results of Phase II clinical trial for CPL’ 116, a JAK/ROCK dual inhibitor in the treatment of Rheumatoid Arthritis (RA)
Celon Pharma S.A. (CLN.WA) today announced the successful completion of a Phase 2 trial a JAK/ROCK dual inhibitor in the treatment of Rheumatoid Arthritis (RA).
June 17, 2024
·
7 min read
Rare diseases
Facing a Dearth of Big Pharma Interest, Rare Disease Players Get Creative to Fund R&D
A handful of billion-dollar deals in the rare disease space highlights the uptick in Big Pharma’s investment, but it’s still extremely low compared to the money flowing to more common indications.
November 20, 2024
·
7 min read
·
Heather McKenzie
China
Big Pharma Rushes to China for Deal Prospecting Despite Regulatory Uncertainty
China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.
January 7, 2025
·
6 min read
·
Annalee Armstrong
MASH
Boston Pharma Carves Out Monthly Treatment Niche in MASH With Strong Phase II Data
Boston Pharma’s once-monthly injection efimosfermin alfa offers a convenient dosing option for MASH patients while also achieving promising rates of fibrosis and MASH improvement, according to a Phase II readout.
November 18, 2024
·
2 min read
·
Tristan Manalac
Drug Development
Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise
Erasca, Inc. announced it has entered into exclusive license agreements for two preclinical RAS programs—a potential best-in-class pan-RAS molecular glue and a potential first-in-class pan-KRAS inhibitor —and provided a pipeline update.
May 16, 2024
·
10 min read
Press Releases
Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers
January 23, 2025
·
13 min read
Press Releases
LAPIX Therapeutics Doses First Patient-In Phase 1b Clinical Trial of LPX-TI641 for Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA)
January 23, 2025
·
3 min read
Editorial
Pharma’s Q3 Was a Rollercoaster Ride. Let’s Do It Again Next Quarter
Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.
November 15, 2024
·
3 min read
·
Annalee Armstrong
Press Releases
CORXEL Acquires Worldwide (excluding Greater China) Rights to an Oral Small Molecule GLP-1 RA for the Treatment of Obesity and Diabetes
December 23, 2024
·
3 min read
Press Releases
Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise
October 25, 2024
·
10 min read
1 of 57,702
Next
